Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03723655 · ClinicalTrials.gov registry record · Phase 2
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 314
- Enrollment target
NCT03723655 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 314 participants.
The verdict
NCT03723655, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 314 participants
- Enrollment target
Study Summary
Approximately 30 sites that enrolled participants in the MAVERICK-HCM (MYK-461-006) study in the United States (US) will initiate this study. Approximately 90 sites that enrolled participants in the EXPLORER-HCM (MYK-461-005) study in the US, Europe, and Israel will initiate this study. Note: Approximately 30 centers overlap between MAVERICK and EXPLORER.
Interventions
- DRUG mavacamten
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2018-09-27 |
| Est. Completion | 2026-01-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03723655
The ClinicalTrials.gov registry entry for NCT03723655 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 314 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which mavacamten is the first listed.
NCT03723655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03723655 about?
NCT03723655 is a clinical study titled "A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM". Approximately 30 sites that enrolled participants in the MAVERICK-HCM (MYK-461-006) study in the United States (US) will initiate this study. Approximately 90 sites that enrolled participants in the EXPLORER-HCM (MYK-461-005) study in the US, Europe, and Israel will initiate this study. Note: Appr...
What is the current status of trial NCT03723655?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 314 participants. The study started on 2018-09-27. Estimated completion is 2026-01-16.
What interventions are being tested in trial NCT03723655?
The interventions under investigation include: mavacamten (DRUG).
Who is sponsoring clinical trial NCT03723655?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.